Published in Cancer Biol Ther on August 10, 2004
mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther (2006) 1.56
Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res (2009) 1.54
OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol (2008) 1.52
Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther (2008) 1.48
Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res (2010) 1.34
mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev (2010) 1.30
PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res (2010) 1.23
hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing. J Clin Invest (2010) 1.20
MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Mol Cancer Ther (2009) 1.08
PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells. Autophagy (2008) 1.06
Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells. Mol Pharmacol (2009) 1.06
Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther (2010) 1.04
OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins. Cancer Biol Ther (2010) 1.03
The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther (2010) 0.98
Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery. Cancer Biol Ther (2010) 0.95
MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anticancer Drugs (2010) 0.91
Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction. Cancer Res (2013) 0.89
Recombinant interleukin-24 lacks apoptosis-inducing properties in melanoma cells. PLoS One (2007) 0.87
RNAi-mediated inhibition of MSP58 decreases tumour growth, migration and invasion in a human glioma cell line. J Cell Mol Med (2010) 0.87
Melanoma differentiation-associated gene-7, MDA-7/IL-24, selectively induces growth suppression, apoptosis in human hepatocellular carcinoma cell line HepG2 by replication-incompetent adenovirus vector. World J Gastroenterol (2006) 0.84
MDA-7/IL-24 inhibits Nrf2-mediated antioxidant response through activation of p38 pathway and inhibition of ERK pathway involved in cancer cell apoptosis. Cancer Gene Ther (2014) 0.82
Enhancing CHK1 inhibitor lethality in glioblastoma. Cancer Biol Ther (2012) 0.81
Myeloid cells migrate in response to IL-24. Cytokine (2011) 0.80
Notch1 downregulation combined with interleukin-24 inhibits invasion and migration of hepatocellular carcinoma cells. World J Gastroenterol (2015) 0.79
Oncolytic adenovirus SG600-IL24 selectively kills hepatocellular carcinoma cell lines. World J Gastroenterol (2010) 0.79
OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2. BMC Cancer (2013) 0.78
Recombinant adenovirus IL-24-Bax promotes apoptosis of hepatocellular carcinoma cells in vitro and in vivo. Cancer Gene Ther (2010) 0.77
Potential use of MDA-7 as a biological adjuvant for radiation therapy. Cancer Biol Ther (2004) 0.75
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol (2008) 21.53
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol (2007) 16.81
Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol (2013) 11.47
Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol (2011) 10.82
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol (2009) 9.25
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature (2005) 7.19
Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain (2005) 6.81
Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science (2007) 6.75
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med (2008) 5.91
Interleukin-10 and related cytokines and receptors. Annu Rev Immunol (2004) 5.41
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Paraneoplastic syndromes of the CNS. Lancet Neurol (2008) 4.62
Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol (2005) 4.10
mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci U S A (2002) 3.99
Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol (2009) 3.97
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res (2007) 3.92
Clinical analysis of anti-Ma2-associated encephalitis. Brain (2004) 3.89
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res (2006) 3.72
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59
Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol (2014) 3.40
Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal (2010) 3.35
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell (2010) 3.34
Bile acids as regulatory molecules. J Lipid Res (2009) 3.23
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res (2006) 3.15
MAPK pathways in radiation responses. Oncogene (2003) 3.12
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem (2005) 3.08
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer (2004) 3.05
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther (2008) 2.96
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther (2007) 2.89
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev (2013) 2.86
Vorinostat. Nat Rev Drug Discov (2007) 2.83
New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res (2010) 2.82
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol (2008) 2.71
Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis. Cancer Res (2006) 2.60
Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene (2005) 2.58
Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther (2007) 2.56
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res (2003) 2.49
Molecular basis of nuclear factor-kappaB activation by astrocyte elevated gene-1. Cancer Res (2008) 2.45
Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. Blood (2010) 2.45
Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res (2010) 2.41
Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proc Natl Acad Sci U S A (2006) 2.38
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res (2003) 2.30
Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell (2009) 2.28
Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol (2009) 2.23
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res (2004) 2.23
A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood (2008) 2.22
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther (2009) 2.21
Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet (2013) 2.20
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem (2004) 2.18
Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res (2010) 2.13
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res (2011) 2.13
Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. Proc Natl Acad Sci U S A (2009) 2.10
Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem (2008) 2.08
The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol (2007) 2.07
Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol (2003) 2.05
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (2013) 2.00
Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol (2010) 1.97
Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood (2006) 1.95
Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res (2008) 1.94